Rabbit anti-Human CD161 Monoclonal Antibody for FC - Q12918

Core Product Specifications and Parameters

Biological Background: CD161 (KLRB1) Function and Localization

• CD161 (KLRB1) is a killer cell lectin-like receptor subfamily B member 1, also known as NKR-P1A, CLEC5B, and NKRP1A.
• It functions as an inhibitory receptor on natural killer (NK) cells, suppressing cytotoxicity.
• Activation stimulates acid sphingomyelinase/SMPD1, elevating intracellular ceramide levels, and also activates AKT1/PKB and RPS6KA1/RSK1 kinases.
• Receptor engagement enhances T-cell proliferation induced by anti-CD3 stimulation.
• The extracellular C-type lectin domain binds the Gal-alpha(1,3)Gal and N-acetyllactosamine carbohydrate epitopes, as well as the endogenous ligand CLEC2D/LLT1.
• Binding to CLEC2D/LLT1 inhibits NK cell-mediated cytotoxicity and interferon-gamma secretion in target cells.
• CD161 is a transmembrane glycoprotein containing a signal-anchor, a transmembrane helix, and a disulfide bond.
• It is selectively expressed on NK cells in the intestinal epithelium and liver, and on memory phenotype T-cells in peripheral blood.

Experimental Guidance and Technical Tips

• The immunogen encompasses the extracellular domain (amino acids 67–225), including the C-type lectin region, facilitating recognition of the native receptor.
• This conjugate is ready for direct flow cytometry staining; titrate to determine the optimal concentration for your cell population.
• Validate antibody performance in the relevant sample system, such as human peripheral blood mononuclear cells or isolated NK/T-cell subsets.
• The antibody is specific for human CD161; cross-reactivity with other species has not been determined and should be verified if required.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, laboratories, and research institutes with one-stop access to IVD raw materials and technical solutions. This anti-CD161 monoclonal antibody supports research into NK cell biology and immune cell phenotyping. By offering validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and sourcing for rare-target raw materials, we help streamline your assay development from concept to clinic.